Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

PURPOSE: The Adjuvant Paclitaxel and Trastuzumab trial was designed to address treatment of patients with small human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The primary analysis of the Adjuvant Paclitaxel and Trastuzumab trial demonstrated a 3-year disease-free survival (D...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Tolaney, Sara M., Guo, Hao, Pernas, Sonia, Barry, William T., Dillon, Deborah A., Ritterhouse, Lauren, Schneider, Bryan P., Shen, Fei, Fuhrman, Kit, Baltay, Michele, Dang, Chau T., Yardley, Denise A., Moy, Beverly, Marcom, P. Kelly, Albain, Kathy S., Rugo, Hope S., Ellis, Mathew J., Shapira, Iuliana, Wolff, Antonio C., Carey, Lisa A., Overmoyer, Beth, Partridge, Ann H., Hudis, Clifford A., Krop, Ian E., Burstein, Harold J., Winer, Eric P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
RAPID COMMUNICATION
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7587424/
https://ncbi.nlm.nih.gov/pubmed/30939096
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00066
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados